BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35752279)

  • 1. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study.
    Cavaliere C; Segatto M; Ciofalo A; Colizza A; Minni A; Messineo D; Lambiase A; Greco A; de Vincentiis M; Masieri S
    Immunol Lett; 2022 Aug; 248():70-77. PubMed ID: 35752279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
    Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
    Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a real life study.
    Santomasi C; Buonamico E; Dragonieri S; Iannuzzi L; Portacci A; Quaranta N; Carpagnano GE
    Acta Biomed; 2023 Feb; 94(1):e2023028. PubMed ID: 36786266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
    Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
    Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
    Tversky J; Lane AP; Azar A
    Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study.
    Nolasco S; Crimi C; Pelaia C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Campisi R; Valenti G; Vatrella A; Crimi N
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4371-4380.e4. PubMed ID: 34419679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps.
    Matsuno O; Minamoto S
    Pulm Pharmacol Ther; 2020 Oct; 64():101965. PubMed ID: 33039667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma].
    Boiko NV; Lodochkina OE; Kit MM; Kuleshova VG; Nedashkovskaya NG
    Vestn Otorinolaringol; 2021; 86(2):43-48. PubMed ID: 33929151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
    Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V
    J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxycycline may be more clinically effective in type 2 chronic rhinosinusitis nasal polyp comorbid with asthma.
    Paçacı Çetin G; Arslan B; Yılmaz İ
    J Asthma; 2024 Jan; 61(1):20-26. PubMed ID: 37437223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP.
    Guo CL; Liu FF; Wang DY; Liu Z
    Curr Allergy Asthma Rep; 2023 Dec; 23(12):703-713. PubMed ID: 37987873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
    Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
    Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma.
    De Corso E; D'Amato M; Carpagnano GE; Pelaia G; Bonini M
    Curr Allergy Asthma Rep; 2023 May; 23(5):237-248. PubMed ID: 36995525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
    Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S
    Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease].
    Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588
    [No Abstract]   [Full Text] [Related]  

  • 16. Dupilumab (Dupixent
    Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
    Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiological Versus Clinical 1-Year Outcomes of Dupilumab in Refractory CRSwNP: A Real-Life Study.
    Giombi F; Pace GM; Nappi E; Giunta G; Muci G; Pirola F; Ferreli F; Heffler E; Paoletti G; Giannitto C; Mercante G; Francone M; Spriano G; Canonica GW; Malvezzi L
    Laryngoscope; 2024 Jun; 134(6):2626-2633. PubMed ID: 38126613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxycycline Improves Quality of Life and Anosmia in Chronic Rhinosinusitis With Nasal Polyposis: A Randomized Controlled Trial.
    Nabavi M; Arshi S; Bemanian MH; Fallahpour M; Shokri S; Sabouri S; Moosavian F; Nazari J; Bakrani V; Atashrazm F
    Am J Rhinol Allergy; 2023 Jul; 37(4):384-390. PubMed ID: 36740870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.